Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Eagle Pharmaceuticals stock opened at $1.23 on Tuesday. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81. The stock has a 50-day simple moving average of $0.80 and a 200-day simple moving average of $1.70.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. DGS Capital Management LLC boosted its stake in Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the period. Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at about $96,000. RBF Capital LLC boosted its stake in shares of Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Eagle Pharmaceuticals during the third quarter worth about $453,000. Finally, Creative Planning acquired a new position in Eagle Pharmaceuticals in the 3rd quarter valued at about $59,000. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.